W ith the widespread use of opioids for noncancer pain, undesired side effects such as sedation, respiratory depression, and gastrointestinal symptoms are common. In particular, opioid-induced constipation (OIC) is a common problem in individuals using chronic opioids. OIC has been defined by Rome IV criteria as an abnormal change from baseline in bowel habits or defecation patterns after initiating opioid therapy, characterized by any of the following: reduced frequency of spontaneous bowel movements (SBMs) (<3 bowel movements/wk), development or worsening of straining to pass bowel movement, a sense of incomplete evacuation, harder stool consistency, or a patient's perception of distress related to bowel habits. 1, 2 The true impact of OIC likely is underestimated owing to underdiagnosis and undertreatment. Current estimates of the prevalence of OIC in trials range from 15% to 70% 2, 3 in patients on chronic opioids, depending on the patient population, number of subjects, type and amount of opioid, definition of OIC, and outcome measurement. OIC can negatively impact an individual's quality of life and work productivity and is associated with significant direct and indirect costs. 4, 5 In addition, approximately a third of patients will reduce or discontinue prescribed opioids in an attempt to improve bowel function, which can result in worsening of pain symptoms. 6 Several newer treatments currently are approved by the Food and Drug Administration (FDA) for the treatment of OIC including the peripherally acting m-opioid-receptor antagonists methylnaltrexone, naloxegol, naloxone, and, recently, naldemedine. In addition, the prescription-strength laxative lubiprostone also has been approved by the FDA for the treatment of OIC. A previous meta-analysis by Ford et al 7 in 2013 included 17 trials and concluded that m-opioid-receptor antagonists are safe and effective for the treatment of OIC. Since then, both naloxegol and naldemedine have been approved by the FDA after completing phase III clinical trials. Therefore, our aim is to update the previous metaanalysis by including additional studies published for the treatment of OIC.
Methods

Search Strategy and Inclusion Criteria
We conducted a search of the medical literature following the protocol outlined in the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement 8 using MEDLINE (1950 to March 2017), EMBASE (Elsevier Science: 1975-present) and EMBASE Classic (1947 to March 2017), Web of Science (Institute for Scientific Information: 1900 to March 2017), and the Cochrane Central Register of Controlled Trials (update software: 1996 to March 2017). Randomized controlled trials (RCTs) evaluating the effect of medical therapy for OIC were eligible for inclusion. Studies using methylnaltrexone, naloxone, naloxegol, alvimopan, prucalopride, lubiprostone, axelopran (TD-1211), and naldemedine were identified. For RCTs that included an open-label extension, only the initial RCT period of studies were included in analyses.
There is no universally accepted definition of OIC across studies. Two definitions of OIC were accepted including constipation associated with initiation of opioids, and fewer than 3 SBMs per week with 1 or more of the symptoms of constipation of hard stools, sensation of incomplete evacuation, or moderate to severe straining in 25% of bowel movements after initiation of opioids. Studies that recruited patients with organic or chronic idiopathic constipation were not eligible. Trials using any dose of pharmacologic therapy were considered, and agents could be compared with each other or with placebo.
Studies on OIC were identified with the following terms: constipation or gastrointestinal transit, chronic constipation, or slow transit. This search also was combined with the studies identified with the following terms: opiate alkaloids or analgesics, opioid, or the following free text terms: opiate, opiate$, opioid, or opioid$. This also was combined with the following: narcotic antagonists, naltrexone, naloxone, naloxegol, mu opioid receptors, serotonin receptor agonists, serotonin receptor agonists, guanylate cyclase-coupled, guanylate cyclase, or chloride channels, as well as methylnatrexone, alvimopan, 5-HT 4 , prucalopride, lubiprostone, linaclotide, naldemedine, or TD-1211. The search was conducted by a medical librarian (J.W.) and confirmed independently by 2 investigators (J.N., M.Z.). The EMBASE database, which produced the greatest number of results, was searched both with keywords and subject terms, and with the McMaster validated Evidence Based Medicine Center Hedge for RCTs. Results of the searches were combined with "OR" and duplicates were removed. Subject experts and the research team selected highly relevant articles and the bibliographies of these articles were searched for additional studies. Articles were assessed independently by 2 investigators (J.N., M.Z.) using predesigned eligibility forms, according to the predefined eligibility criteria (Supplementary Materials and Methods).
Outcome Assessment
The primary efficacy outcomes were defined as the efficacy of the therapy to fail compared with placebo. If possible, the author's prespecified outcome measure was used. The most common primary outcome was 3 or more complete SBMs a week over the trial period. If the primary end point could not be extracted through this method and responses from the authors could not be obtained, attempts were made to extract other clinically meaningful outcomes (eg, improvement in SBMs, and so forth). Secondary efficacy outcomes included overall adverse events as well as diarrhea, abdominal pain, nausea, and vomiting.
Data Extraction
All data were extracted independently by 2 investigators onto a Microsoft (Richmond, VA) Excel spreadsheet as a response or no response to pharmacologic treatment. The following clinical data also were extracted for each trial: setting (primary, secondary, or tertiary care), number of study centers, study country or countries, number of female patients, dose and duration of therapy, concomitant medications allowed, OIC criteria used, and primary outcome measure used to define response to therapy. Data were extracted as intention-totreat analyses, with drop-outs assumed to be treatment failures, wherever trial reporting allowed ( Table 1) .
Assessment of Bias Risk and Grading of Recommendation, Assessment, Development, and Evaluation
The Cochrane Collaboration's risk of bias tool was used to assess bias at the individual study level (J.N., M.Z.) (Supplementary Table 1 ). Disagreements were resolved by discussion with the third investigator (A.L.).
The overall quality or certainty of evidence was assessed using the Grading of Recommendation, Assessment, Development, and Evaluation 9 framework. The overall quality or certainty of evidence across all outcomes was classified as high, moderate, low, or very low. A summary of findings table, generated from the GradePro GDT 10 
Data Synthesis and Statistical Analysis
Data were pooled using random-effects models. The effects of each pharmacologic agent in OIC were expressed as the relative risk (RR) of failure to respond to therapy compared with placebo, with 95% CIs. For studies that had multiple treatment groups with the same drug (eg, comparing different dose levels), the groups were combined for analyses. The rate of adverse events also was expressed as the RR for developing an adverse event on drug compared with placebo. The number needed to treat (NNT) was defined as the number of patients who would need to receive active therapy, over and above the placebo therapy, for 1 patient to experience an improvement in symptoms. The number needed to harm (NNH) was defined as the number of patients who would need to receive active therapy, over and above placebo therapy, for 1 patient to experience an adverse event leading to withdrawal. The NNT and NNH were calculated from the reciprocal of the absolute risk difference for efficacy and adverse events, respectively.
All analyses were conducted with the Metafor package 11 (Maastricht, Netherlands) for R. 12 Forest plots were generated to examine the mean RR for each drug (with 95% CIs). Funnel plots also were created to assess for evidence of asymmetry, and therefore possible publication bias or other small study effects. Heterogeneity across studies and drugs was measured using the Q statistic, 13 which follows a chi-square distribution, and I 2 . 14,15 Possible sources of residual heterogeneity were explored in sensitivity analyses. Specifically, subgroup analyses were used to evaluate differences of effect in studies with cancer vs noncancer-related pain as well as laxative vs non-laxativerefractory patient populations. Subgroup analysis also was performed to determine the influence of different primary outcome definitions and study duration. Metaregression also was performed based on baseline opioid dosage and placebo-response rate.
Results
Overall Efficacy of Opioid-Induced Constipation Agents
The search strategy generated 886 citations, 35 of which appeared to be pertinent to the systematic review and were retrieved for further evaluation (Figure 1 ). Of these, there were 26 publications with a total of 28 placebo-controlled trials identified in this meta-analysis; 1 small methylnaltrexone trial was removed because it was a clear outlier 16 (see funnel plot analysis later), resulting in a total sample of 27 trials. All of the studies were published in English. In total, 24 trials evaluated m-opioid-receptor antagonists in OIC including naloxone (n ¼ 5 [17] [18] [19] [20] [21] ), alvimopan (n ¼ 4 [22] [23] [24] [25] , naloxegol (n ¼ 3 26, 27 ), methylnatrexone (n ¼ 7 16, [28] [29] [30] [31] [32] ), naldemedine (n ¼ 4 [33] [34] [35] , and axelopran (TD-1211) (n ¼ 1 36 ). In addition, 4 trials examined drugs that were not m-opioid-receptor antagonists in the treatment of OIC, including 3 trials with lubiprostone 37-39 and 1 with prucalopride. 40 Characteristics of each trial can be seen in Table 1 . Each study's bias risk was assessed (Supplementary Table 1 ). The overall quality of evidence was evaluated with the Grading of Recommendation, Assessment, Development, and Evaluation assessment ( Table 2) .
A funnel plot with all studies showed significant asymmetry (Egger test: Z ¼ -5.06; P < .001), with 1 clear outlier, 16 a small methylnaltrexone study that found results strongly in favor of the drug and was inconsistent with other methylnaltrexone studies. In this study, all 11 participants administered the drug had a favorable response, and none of the 11 participants administered placebo had a response. After removing this trial, the funnel plot still was significantly asymmetric (Z ¼ -4.79; P < .001), but with outliers with regard to both high and low efficacy ( Figure 2 ) that Adapted from Ford et al. 7 could be partially owing to the inclusion of multiple drug classes and the overall heterogeneity among the 27 remaining trials (heterogenity across studies [Q](26) ¼ 105.0; P < .001; I 2 ¼ 77.9%). A comparison between low-bias (RR, 0.67; 95% CI, 0.58-0.78) and other trials (RR, 0.71; 95% CI, 0.64-0.78) showed no significant difference with regard to efficacy (Q(1) ¼ 0.23; P ¼ .63); thus, no trials were removed for reasons pertaining to suspected bias.
In total, 5390 participants were randomized to receive drug treatment and 3491 received placebo. A total of 2784 (51.3%) of those who received the drug had a favorable response, compared with 1157 (33.1%) of individuals randomized to placebo, for an overall NNT of 5 ( Figure 3) . The overall RR for failure to respond to therapy was significantly lower for those who received drug rather than placebo treatment (RR, 0.70; 95% CI, 0.64-0.75). When this analysis was restricted to solely drugs and dosage levels that have been FDA approved for the treatment of OIC (ie, lubiprostone, methylnaltrexone, naldemedine, naloxegol, and naloxone), the RR was 0.69 (95% CI, 0.62-0.77) with an NNT of 5 (95% CI, 4-7). Individually, the NNTs for lubiprostone, naloxegol, methylnaltrexone, naloxone, and naldemedine were as follows: 15 (95% CI, 9-51), 7 (95% CI, 4-26), 3.4 (95% CI, 3-6), 4 (95% CI, 4-6), and 5 (95% CI, 4-8), respectively. NOTE. The GRADE Working Group grades of evidence were as follows: high quality: we are very confident that the true effect lies close to that of the estimate of the effect; moderate quality: we are moderately confident in the effect estimate, the true effect is likely to be close to the estimate of the effect but there is a possibility that it is substantially different; low quality: our confidence in the effect estimate is limited, the true effect may be substantially different from the estimate of the effect; and very low quality: we have very little confidence in the effect estimate, the true effect is likely to be substantially different from the estimate of effect. GRADE, Grading of Recommendation, Assessment, Development, and Evaluation; RCT, randomized controlled trial; RR, relative risk.
a
The I 2 was 77%, but we did not rate down for inconsistency because some of the heterogeneity could be explained by different patient populations. Three studies of methylnaltrexone in individuals with cancer-related pain had significantly better results (Q(1) ¼ 7.44; P ¼ .006) in favor of the drug than 3 studies in individuals with non-cancer-related pain. Because the test of interaction was significant, we presented the effects of methylnaltrexone in these 2 populations as separate effect estimates. b We rated down for risk of bias because there were concerns about randomization, allocation concealment, and blinding in some of the studies. c We rated down for inconsistency (I 2 ¼ 56.3%). Some heterogeneity between trials may be owing to different dosages: 0.5-1 mg/d compared with 1-2 mg/d. d We rated down for inconsistency, which may be attributed to different patient populations. One study 42 was in patients with cancer-related pain whereas the other 3 studies were in patients with non-cancer-related pain.
43,44
e There was significant heterogeneity across studies with I 2 ¼ 86%, therefore we rated down for inconsistency. f We rated down for the following: unclear risk of bias, additionally, 1 study did not have optimal information size (few events).
Given the heterogeneity observed in the included studies, meta-regression then was performed for possible moderating factors. The mean dosage of opioids at baseline in each study (converted to morphine equivalents) was a significant predictor of trial outcome (Q(1) ¼ 4.75; P ¼ .029), with higher doses associated with a lower RR. For example, studies with baseline morphine equivalent doses of 100, 200, and 400 mg had predicted RRs of 0.79, 0.69, and 0.54, respectively. Second, the placebo response rate was evaluated. A wide range of placebo responses were observed across trials, ranging between 0% 17 and 56%. 22 However, the proportion of placebo responders was not significantly related to the overall RR (Q(1) ¼ 2.13; P ¼ .145); that is, studies with higher rates of placebo responders also tended to have higher rates of drug responders, and the difference between drug and placebo appeared to be independent from the proportion of placebo responders within each trial.
Sensitivity analysis was performed to determine if the primary outcome of interest accounted for heterogeneity. Six studies 22, 23, 26, 34, 36, 41 used a more stringent outcome criteria, defined as improvement in weekly complete SBM and more than 3 bowel movements per week; however, these 6 studies did not have a significantly different RR (0.75; 95% CI, 0.68-0.83) compared with the other 21 studies (RR, 0.68; 95% CI, 0.61-0.75; Q(1) ¼ 0.83; P ¼ .364). Furthermore, sensitivity analysis in regard to laxative status showed that laxativerefractory populations had superior efficacy with treatment (RR of failure, 0.57; 95% CI, 0.47-0.69) than studies with non-laxative-refractory populations (RR of failure, 0.75; 95% CI, 0.69-0.82; Q(1) ¼ 6.89; P ¼ .009). With regard to study duration, 5 trials 28,29,31-33 had a duration of 2 weeks or fewer, and had a significantly superior response to drug treatment (RR of failure, 0.67; 95% CI, 0.61-0.74) compared with the other 22 trials (RR of failure, 0.85; 95% CI, 0.82-0.88; P < .001). However, among these 22 trials, there was not a significant difference (Q(1) ¼ 3.43; P ¼ .064) between trials with a duration ranging between 3 and 11 weeks 17, 19, 20, 24, 25, 30, 36, 40, 41 (k ¼ 10; RR, 0.81; 95% CI, 0.77-0.86) and trials that were 12 weeks or longer 18, [21] [22] [23] 26, 27, 34, [37] [38] [39] (k ¼ 12; RR, 0.87; 95% CI, 0.83-0.91). Thus, although the shortest trials appeared to have the greatest efficacy, there was not a clear systematic relationship between overall trial duration and RR.
Methylnaltrexone. In total, 6 RCTs studied the use of methylnaltrexone in OIC after removing the small trial by Yuan et al 16 as described earlier. A total of 1619 patients participated in these trials, including 1004 patients who received dosages of methylnatrexone ranging from as low as 12 mg [28] [29] [30] 32 to 450 mg, 41 from 0.5 to 4 weeks in duration. Methylnaltrexone was significantly more efficacious than placebo (RR, 0.62; 95% CI, 0.49-0.78; P < .001). Of the 1004 individuals who received methylnatrexone, 485 (48.3%) failed to respond compared with 442 of 618 patients on placebo (71.5%). There was significant heterogeneity between studies (Q(5) ¼ 28.18; P < .001; I 2 ¼ 77.2). Three studies 29,31,32 with patients with cancer-related pain had significantly better results in favor of the drug (RR, 0.51; 95% CI, 0.41-0.63) than studies 28, 30, 41 with non-cancer-related pain (RR, 0.75; 95% CI, 0.63-0.90; Q(1) ¼ 7.44; P ¼ .006). After accounting for this variable as a moderator, the residual heterogeneity in methylnaltrexone studies was no longer significant (Q(4) ¼ 7.37; P ¼ .118; I 2 ¼ 46.9). Only 1 study 41 examined the other FDA-approved dose level of 450 mg, which had an RR of 0.79 (95% CI, 0.66-0.94). The overall quality of evidence was high.
Naloxone. Five total trials [17] [18] [19] [20] [21] examined the use of naloxone in OIC. A total of 482 patients received naloxone for a duration of 3 to 12 weeks, and 212 (43.9%) failed to respond compared with 250 of 356 patients on placebo (70.2%) (RR, 0.63; P < .001). There was no significant heterogeneity across studies (Q(4) ¼ 1.23; P ¼ .873; I 2 ¼ 0.0%). Because we rated down for risk of bias, the overall quality of evidence was moderate.
Alvimopan. Four trials examined the use of alvimopan compared with placebo. [22] [23] [24] [25] Overall, 433 of 1060 (40.8%) patients receiving alvimopan failed to respond compared with 280 of 519 (53.9%) patients on placebo. Three trials evaluated dosages of 0.5 and 1 mg daily, [22] [23] [24] but the fourth trial used both a 1-and 2-mg total daily dosage. 25 Alvimopan was significantly more efficacious than placebo with a RR of failure of 0.68 (P < .001), with some heterogeneity between trials (Q(3) ¼ 6.86; P ¼ .076; I 2 ¼ 56.3%). This heterogeneity was explained by 1 study 25 that used a higher dosage compared with the other trials and also showed the lowest RR of failure in the treatment of OIC. Because we rated down for inconsistency, the overall quality of evidence was moderate.
Naldemedine. In total, there were 4 phase III RCTs of naldemedine. [33] [34] [35] Overall, 367 of 823 (44.6%) patients on naldemedine failed to respond compared with 459 of 702 (65.4%) patients on placebo. The drug was significantly more efficacious than placebo (RR, 0.65; P < .001), with significant heterogeneity across trials (Q(3) ¼ 11.20; P ¼ .011; I 2 ¼ 79.6%), mostly owing to 1 trial 33 that had more favorable results for the drug compared with the other trials. In this study, naldemedine was randomized among cancer-related pain patients with 28.8% not responding on naldemedine compared with 65% on placebo. Comparatively, the 3 large studies 34, 35 examined noncancer patients with chronic pain, with 339 of 726 (46.7%) failing to respond to naldemedine compared with 397 of 607 who received placebo (65.4%). The overall quality of evidence was moderate because we rated down for inconsistency. Naloxegol. Three trials 26, 27 examined naloxegol compared with placebo. In total, 1522 patients were randomized to placebo or naloxegol. Of these, 572 of 981 (58.3%) patients who received naloxegol failed to respond, compared with 382 of 541 (70.6%) who received placebo; the overall RR for naloxegol compared with placebo was 0.77 (95% CI, 0.61-0.97; P ¼ .026). The 2 trials 26 that compared the 12.5-and 25-mg dose levels (the 2 doses currently approved by the FDA) did not find a significant difference in efficacy (RR for a superior response for 25 mg compared with 12 mg, 1.11; 95% CI, 0.94-1.30; P ¼ .208). There was significant heterogeneity among the 3 trials (Q(2) ¼ 8.44; P ¼ .015; I 2 ¼ 86.4%), primarily because 1 study 27 found superior efficacy compared with the other 2 trials, 26 which both were conducted by the same research group. Because we rated down for inconsistency, the overall quality of evidence was moderate.
Lubiprostone. Three trials [37] [38] [39] examined lubiprostone compared with placebo. Of 647 patients on lubiprostone, 400 (61. 8%) failed to respond compared with 438 of 637 (68.8%) patients who received placebo. There was no significant heterogeneity among the 3 trials (Q(1) ¼ 1.40; P ¼ .50; I 2 ¼ 0.0%). These studies provide modest evidence supporting lubiprostone compared with placebo (RR, 0.90; 95% CI, 0.83-0.97; P ¼ .005). The overall quality of evidence was high.
Prucalopride and axelopran (TD-1211). Only 1 placebo-controlled, double-blind trial has examined prucalopride, 40 with modest results in favor of the drug (RR, 0.88; 95% CI, 0.68-0.98; P ¼ .032). Likewise, only 1 trial 36 has been conducted examining axelopran (TD-1211), providing evidence to support superior efficacy compared with placebo (RR, 0.60; 95% CI, 0.44-0.81; P ¼ .001). The overall quality of evidence was high for prucalopride and moderate for axelopran (we rated down for imprecision).
Adverse Effects
Twenty-three placebo-controlled RCTs provided data regarding adverse events experienced within each group. In these trials, 58.2% of participants given a drug experienced at least 1 new-onset adverse event, compared with 53.0% of those given placebo. This difference was significant (incidence rate ratio, 1.10; 95% CI, 1.05-1.16; P < .001), with an overall NNH of 21 and no significant heterogeneity across trials (Q(22) ¼ 22.26; P ¼ .44; I 2 ¼ 0.0%). Thus, the frequency of adverse effects (Table 3) combined across all drug classes. Where available, data for the 3 most common adverse effects of diarrhea (k ¼22), abdominal pain (k ¼ 22), and nausea/vomiting (k ¼ 19) also were extracted. Participants who received a study drug were significantly more likely to experience all 3 adverse events compared with placebo (P < .009). The overall drop-out rate owing to adverse events (only 20 studies reported these data) were 7.4% and 4.7% for drug and placebo, respectively (P ¼ .002), resulting in an NNH of 36 (95% CI, 22-96).
Discussion
The purpose of this systematic review and metaanalysis is to provide a synthesis of the growing literature on available OIC treatment. Our findings further support the efficacy of m-opioid-receptor antagonists in the treatment of OIC. Despite variable medication dosages and significant heterogeneity across studies, all studies showed the superiority of these agents compared with placebo. With the addition of newer agents to treat OIC, this shows a slightly higher overall number needed to treat of 5 compared with the previous meta-analysis. 7 The systematic review and meta-analysis of naloxegol, methylnaltrexone, naloxone, and naldemedine provided moderate-to high-quality evidence.
After pooling all treatment for OIC, adverse effects were significantly higher in those receiving active drug compared with placebo, with a NNH of 20. Among the specific adverse events, participants who received drug treatment were significantly more likely to experience diarrhea, abdominal pain, and nausea/vomiting compared with placebo, although the frequencies for these events were still relatively low in drug-treated groups (8.5%, 12.8%, and 11.5% for diarrhea, abdominal pain, and nausea/vomiting, respectively). This metaanalysis confirms the overall safety of these medications in more than 5000 patients receiving m-opioid antagonists while maintaining an opioid analgesic affect.
Although a limitation of this study was the significant heterogeneity across 27 studies, we have shown through sensitivity analysis and meta-regression the potential factors contributing to this heterogeneity. This is likely owing to the inclusion of multiple agents, varying baseline opioid use, and different subject populations (cancer vs non-cancer-related pain). Baseline narcotic dosage ranged from morphine equivalents of 20 to 2000 mg, not mentioned in other studies. 29, 31, 32, 38, 39 Opioid types varied from oxycodone to morphine to methadone. Although the type of opioid should not influence the prevalence of OIC, the differences in frequency and dosage may account for differences in symptom severity. In 1 study, daily use of opioids led to constipation in 81% compared with 46% of patients taking opioids only up to 3 times a week. 4 We have shown that a higher baseline morphine equivalent dosage was associated with proportionately superior efficacy. Likewise, populations that were refractory to laxatives also showed superior efficacy. Both of these findings suggest that the subset of patients on opioids with more severe constipation respond more favorably to agents targeted mechanistically against m-opioid receptors. On the other hand, OIC criteria and the duration of studies did not influence outcome in the treatment of OIC.
Three trials using lubiprostone and 1 using prucalopride showed that both agents were efficacious in the treatment of OIC; however, both drugs were comparatively less efficacious when compared with m-opioid-receptor antagonists, supporting previous findings. 7 The NNT of lubiprostone was higher at 15 compared with other m-opioid-receptor antagonists. Laxatives often are used as first-line therapy in OIC. The effect of over-the-counter laxatives in the treatment of OIC, however, is difficult to assess owing to variable methodology, missing data, and risk of bias. 42, 43 Although our analysis supports the use of lubiprostone for OIC compared with placebo, prescription laxatives may not be superior to over-the-counter laxatives.
Despite FDA approval for the m-opioid antagonists naloxegol, methylnatrexone, fixed-dosage oxycodone/ naloxone, and naldemedine, no formal guidelines exist for their use in clinical practice; thus, making them underused. Although some consensus 44 is developing in regards to using these agents in clinical practice for those patients with chronic pain on opiate treatment, this provides further evidence showing the efficacy and safety of m-opioid-receptor antagonists and lubiprostone in the treatment of OIC. 45 
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